111 - John F. Enders Lecture

Friday, October 18, 2024

9:15 AM – 10:00 AM US PT

Location: Ballroom (West Hall B)

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 0.75 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 0.75 hours of MOC Credit
CNE Credits: Maximum of 0.75 hours of ANCC Credit
ACPE Credits: ACPE 0.75 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Emily Erbelding, MD (she/her/hers)

Director, Division of Microbiology and Infectious Disease NIAID
National Institutes of Health
Rockville, MD, United States

Faculty(s)

Timothy Uyeki, MD, MPH, MPP (he/him/his)

Chief Medical Officer, Influenza Division, National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Atlanta, GA, United States

Disclosure(s):

Emily Erbelding, MD: No financial relationships to disclose

Timothy M. Uyeki, MD, MPH, MPP: No financial relationships to disclose

John F. Enders, PhD, served as the second president of IDSA. Dr. Enders and
two of his colleagues received the 1954 Nobel Laureate in Medicine for their
discovery of the ability of poliomyelitis viruses to grow in cultures of various
types of tissue. This discovery led to the development of vaccines against polio,
measles, rubella and mumps. His contributions, which include major advances
in the field of genetics, links between viruses and cancer and insights into the
pattern and process of tumor growth, are noted among the most important of
the 20th century. The John F. Enders Distinguished Lecture in Medical Virology,
which bears his name, was first given in 1988 by Thomas Weller, MD.

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe the epidemiology of human H5N1 cases worldwide since 1997;
discuss the clinical characteristics of human H5N1 cases and clinical management issues, including antiviral use;
summarize the clinical features of infections with other novel influenza A viruses of pandemic potential.

Presentations:

9:15 AM – 9:35 AM US PT

Awards Presentation
9:35 AM – 10:00 AM US PT

Human Infections with Highly Pathogenic Avian Influenza A(H5N1) Viruses and Pandemic Influenza Threats
Speaker: Timothy M. Uyeki, MD, MPH, MPP (he/him/his) – Centers for Disease Control and Prevention